International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The main goal of this study is to improve the outcome of children and adolescents with acute
lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies
within a large international trial and the integration of new agents.
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
Australian & New Zealand Childhood Hematology & Oncology Group (Co-Sponsor Australia/NZ) Australian & New Zealand Children's Haematology/Oncology Group Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK) Centre Hospitalier Universitaire de Nice CHU de NICE, Hôpital L'ARCHET (co-sponsor, France) Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark) EORTC (Co-Sponsor Belgium) European Organisation for Research and Treatment of Cancer - EORTC Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal) Karolinska University Hospital Stockholm (co-sponsor, Sweden) Medical University of Wroclaw (Co-Sponsor Poland) Oslo University Hospital (co-sponsor, Norway) Ospedale Pediatrico Bambino (co-sponsor, Italy) Our Lady's Chilrden's Hospital (Co-Sponsor Ireland) Prinses Máxima Centrum (Co-Sponsor Netherlands) Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain) St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria) Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel) Turku University Central Hospital (co-sponsor, Finland) University Children's Hospital Zürich (co-sponsor, Switzerland) University Children's Hospital, Zurich University Hospital Motol (Co-Sponsor Czech Republic)